| Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed (NCT06102759) | Tianjin Medical University Cancer Institute and Hospital | 2023-11-10 |
| Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer (NCT06102772) | Tianjin Medical University Cancer Institute and Hospital | 2023-11-10 |
| Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer (NCT06093438) | Tianjin Medical University Cancer Institute and Hospital | 2023-11-01 |
| The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer (NCT06208436) | Tianjin Medical University Cancer Institute and Hospital | 2023-10-07 |
| Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC (NCT06061146) | Tianjin Medical University Cancer Institute and Hospital | 2023-10-05 |
| A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy (NCT06208826) | Tianjin Medical University Cancer Institute and Hospital | 2023-09-01 |
| A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative Surgery (NCT06023966) | Tianjin Medical University Cancer Institute and Hospital | 2023-09-01 |
| Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer (NCT05820906) | Tianjin Medical University Cancer Institute and Hospital | 2023-09-01 |
| Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer (NCT05975944) | Tianjin Medical University Cancer Institute and Hospital | 2023-09-01 |
| Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure (NCT06413017) | Tianjin Medical University Cancer Institute and Hospital | 2023-08-31 |
| Personalized SBRT in Early-Stage Peripheral NSCLC (NCT07167459) | Tianjin Medical University Cancer Institute and Hospital | 2023-08-04 |
| Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer (NCT05974059) | Tianjin Medical University Cancer Institute and Hospital | 2023-08-01 |
| A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy (NCT05828875) | Tianjin Medical University Cancer Institute and Hospital | 2023-08-01 |
| HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma (NCT05821361) | Tianjin Medical University Cancer Institute and Hospital | 2023-08-01 |
| Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invasion. (NCT06317324) | Tianjin Medical University Cancer Institute and Hospital | 2023-08-01 |
| Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Biopsy Procedure. (NCT06484764) | Tianjin Medical University Cancer Institute and Hospital | 2023-07-03 |
| Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study (NCT07491159) | Tianjin Medical University Cancer Institute and Hospital | 2023-07-01 |
| Pre-pectoral Breast Reconstruction With or Without Mesh (NCT05888571) | Tianjin Medical University Cancer Institute and Hospital | 2023-07-01 |
| Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients (NCT05947825) | Tianjin Medical University Cancer Institute and Hospital | 2023-07-01 |
| HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma (NCT05864755) | Tianjin Medical University Cancer Institute and Hospital | 2023-06-20 |
| H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis (NCT05872841) | Tianjin Medical University Cancer Institute and Hospital | 2023-06-01 |
| The Possible Range of No.12a Lymph Node Dissection of Locally Advanced Gastric Cancer (NCT06033482) | Tianjin Medical University Cancer Institute and Hospital | 2023-06-01 |
| Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer (NCT05908747) | Tianjin Medical University Cancer Institute and Hospital | 2023-05-31 |
| Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer (NCT06496789) | Tianjin Medical University Cancer Institute and Hospital | 2023-05-27 |
| A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy (NCT05890287) | Tianjin Medical University Cancer Institute and Hospital | 2023-05-16 |
| A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission (NCT05874778) | Tianjin Medical University Cancer Institute and Hospital | 2023-05-15 |
| Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors) (NCT05842018) | Tianjin Medical University Cancer Institute and Hospital | 2023-05-01 |
| Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy (NCT05806671) | Tianjin Medical University Cancer Institute and Hospital | 2023-05-01 |
| A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma (NCT05997147) | Tianjin Medical University Cancer Institute and Hospital | 2023-05-01 |
| Single-center, Prospective Study on the Identification and Delineation of Brain and Lung Tumors and At-Risk Organs, and Functional Testing of Surrounding Tissues Based on Dual-Energy CT (NCT06301100) | Tianjin Medical University Cancer Institute and Hospital | 2023-04-28 |
| Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis (NCT06405685) | Tianjin Medical University Cancer Institute and Hospital | 2023-04-27 |
| Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients (NCT06370065) | Tianjin Medical University Cancer Institute and Hospital | 2023-04-27 |
| Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. (NCT05807776) | Tianjin Medical University Cancer Institute and Hospital | 2023-04-24 |
| Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study (NCT05685550) | Tianjin Medical University Cancer Institute and Hospital | 2023-04-12 |
| Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer (NCT06141226) | Tianjin Medical University Cancer Institute and Hospital | 2023-04-12 |
| Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients (NCT06009627) | Tianjin Medical University Cancer Institute and Hospital | 2023-04-11 |
| Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma (NCT06102746) | Tianjin Medical University Cancer Institute and Hospital | 2023-04-10 |
| A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting (NCT05792228) | Tianjin Medical University Cancer Institute and Hospital | 2023-04-02 |
| Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation (NCT05778149) | Tianjin Medical University Cancer Institute and Hospital | 2023-03-31 |
| Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer (NCT05853172) | Tianjin Medical University Cancer Institute and Hospital | 2023-03-21 |
| Feasibility Study of Radiation Therapy With Wide Detector 4DCT Scanning for Primary or Metastatic Lung Cancer (NCT06233396) | Tianjin Medical University Cancer Institute and Hospital | 2023-03-01 |
| Minimally Invasive Intrathoracic Esophagogastric Side to Side Anastomosis vs. End to Side Anastomosis (NCT05812495) | Tianjin Medical University Cancer Institute and Hospital | 2023-03-01 |
| Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer (NCT05720533) | Tianjin Medical University Cancer Institute and Hospital | 2023-03-01 |
| Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk (NCT05672537) | Tianjin Medical University Cancer Institute and Hospital | 2023-01-20 |
| Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer (NCT05640791) | Tianjin Medical University Cancer Institute and Hospital | 2023-01-12 |
| AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH (NCT05678933) | Tianjin Medical University Cancer Institute and Hospital | 2023-01-01 |
| Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced Diarrhea (NCT07460596) | Tianjin Medical University Cancer Institute and Hospital | 2023-01-01 |
| Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer (NCT05627414) | Tianjin Medical University Cancer Institute and Hospital | 2023-01-01 |
| Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial (NCT05942573) | Tianjin Medical University Cancer Institute and Hospital | 2022-12-24 |
| HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma (NCT05621499) | Tianjin Medical University Cancer Institute and Hospital | 2022-12-20 |
| Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer (NCT05295043) | Tianjin Medical University Cancer Institute and Hospital | 2022-12-10 |
| Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations (NCT05651672) | Tianjin Medical University Cancer Institute and Hospital | 2022-12-02 |
| A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours (NCT05644392) | Tianjin Medical University Cancer Institute and Hospital | 2022-11-25 |
| A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma (NCT05644379) | Tianjin Medical University Cancer Institute and Hospital | 2022-11-24 |
| Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma (NCT05616390) | Tianjin Medical University Cancer Institute and Hospital | 2022-11-09 |
| Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma (NCT05582109) | Tianjin Medical University Cancer Institute and Hospital | 2022-10-30 |
| Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer (NCT05595590) | Tianjin Medical University Cancer Institute and Hospital | 2022-10-20 |
| Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) (NCT05686434) | Tianjin Medical University Cancer Institute and Hospital | 2022-10-14 |
| Early Detection of Pancreatic Cancer (NCT05596435) | Tianjin Medical University Cancer Institute and Hospital | 2022-10-10 |
| A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer (NCT05871918) | Tianjin Medical University Cancer Institute and Hospital | 2022-10-08 |
| Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer (NCT05679050) | Tianjin Medical University Cancer Institute and Hospital | 2022-10-01 |
| Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs at Risk (NCT05787522) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-30 |
| Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy (NCT05560308) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-30 |
| Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma (NCT05535647) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-25 |
| Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research (NCT05885776) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-13 |
| Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC. (NCT05620498) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-08 |
| A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations (NCT05560334) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-08 |
| Toripalimab-based Neoadjuvant Therapy in LA-HNSCC (NCT05522985) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-02 |
| Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma (NCT05683704) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-01 |
| Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis (NCT05524155) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-01 |
| Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer (NCT05507593) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-01 |
| Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (NCT05519410) | Tianjin Medical University Cancer Institute and Hospital | 2022-08-23 |
| Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer (NCT05273814) | Tianjin Medical University Cancer Institute and Hospital | 2022-08-01 |
| A Phase II Study of CRT Combined With QL1706 in ESCC Patients (NCT05490719) | Tianjin Medical University Cancer Institute and Hospital | 2022-08-01 |
| The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer. (NCT05781633) | Tianjin Medical University Cancer Institute and Hospital | 2022-07-20 |
| CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma (NCT05458180) | Tianjin Medical University Cancer Institute and Hospital | 2022-07-07 |
| Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy (NCT05627427) | Tianjin Medical University Cancer Institute and Hospital | 2022-07-01 |
| PD1 and PARP for Maintenance Therapy in NSLLC (NCT05392686) | Tianjin Medical University Cancer Institute and Hospital | 2022-06-20 |
| Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma (NCT05449483) | Tianjin Medical University Cancer Institute and Hospital | 2022-05-11 |
| Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study (NCT06404840) | Tianjin Medical University Cancer Institute and Hospital | 2022-05-06 |
| Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC (NCT04631770) | Tianjin Medical University Cancer Institute and Hospital | 2022-05-01 |
| Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury. (NCT05711459) | Tianjin Medical University Cancer Institute and Hospital | 2022-05-01 |
| An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer (NCT05356351) | Tianjin Medical University Cancer Institute and Hospital | 2022-05-01 |
| Serum Exosomal miRNA Predicting the Therapeutic Efficiency in Lung Squamous Carcinoma (NCT05854030) | Tianjin Medical University Cancer Institute and Hospital | 2022-04-01 |
| Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium (NCT05273827) | Tianjin Medical University Cancer Institute and Hospital | 2022-03-22 |
| Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves During Thoracoscopic Esophagectomy (NCT05199168) | Tianjin Medical University Cancer Institute and Hospital | 2022-03-01 |
| Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation (NCT05263947) | Tianjin Medical University Cancer Institute and Hospital | 2022-01-30 |
| H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study (NCT05167643) | Tianjin Medical University Cancer Institute and Hospital | 2022-01-23 |
| GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma (NCT05215665) | Tianjin Medical University Cancer Institute and Hospital | 2022-01-15 |
| Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma (NCT05251662) | Tianjin Medical University Cancer Institute and Hospital | 2022-01-13 |
| A Study on the Impact of Intelligent Nutrition Management on Clinical Outcomes in Chemotherapy Patients With Gastrointestinal Malignancies (NCT06997302) | Tianjin Medical University Cancer Institute and Hospital | 2022-01-01 |
| Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) (NCT04807673) | Tianjin Medical University Cancer Institute and Hospital | 2021-12-01 |
| Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma (NCT05166772) | Tianjin Medical University Cancer Institute and Hospital | 2021-12-01 |
| Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients (NCT05221775) | Tianjin Medical University Cancer Institute and Hospital | 2021-11-01 |
| Granisetron Transdermal Patch System for Prevention of CINV by CapeOX (NCT05325190) | Tianjin Medical University Cancer Institute and Hospital | 2021-10-10 |
| Clinical Study on Prevention and Treatment of Pyrotinib Associated Diarrhea With Traditional Chinese Medicine (NCT04988165) | Tianjin Medical University Cancer Institute and Hospital | 2021-10-08 |
| A Study of OLR in First-line Treatment of Mantle Cell Lymphoma (NCT05076097) | Tianjin Medical University Cancer Institute and Hospital | 2021-09-30 |
| Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System. (NCT05036798) | Tianjin Medical University Cancer Institute and Hospital | 2021-09-17 |
| Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC (NCT05077839) | Tianjin Medical University Cancer Institute and Hospital | 2021-09-01 |
| SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. (NCT04836520) | Tianjin Medical University Cancer Institute and Hospital | 2021-08-02 |